Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Biovica (Sweden)
h-index: 13
Total citations: 477
Total papers: 58
Homepage:
http://biovica.com/
Recent papers from Biovica (Sweden)
Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis
The Breast · 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial
Clinical Cancer Research · 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial
Clinical Cancer Research · 2026
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial
European Journal of Cancer · 2026
Abstract 1899: Thymidine kinase activity as a translational biomarker to support dose optimization in oncology drug development and a tool for monitoring patients.
Cancer Research · 2026
Abstract 7753: Circulating thymidine kinase activity (TKa) as a predictive and dynamic biomarker in the metastatic non-small cell lung cancer (NSCLC): Immunoblood study
Cancer Research · 2026
Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors
Immuno-Oncology Technology · 2026
47P Serum thymidine kinase activity in older patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib and letrozole in the RibOB trial
ESMO Open · 2025
Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles
Biochemistry and Biophysics Reports · 2024
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.
Journal of Clinical Oncology · 2024
Abstract PO3-13-02: Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
Cancer Research · 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Breast Cancer Research and Treatment · 2024
A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine “Flare” on Positron Emission Tomography
Cancers · 2023
Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study
Scandinavian Journal of Gastroenterology · 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
Biomarkers · 2023
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
npj Breast Cancer · 2022
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Clinical Cancer Research · 2021
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
Frontiers in Oncology · 2021
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
ESMO Open · 2021
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
Journal of Medical Economics · 2021